Investigating the potential of targeting the CB2 receptor for anti-inflammatory disease modification in Parkinson’s disease
Date
2021-10-22Author
Kelly, Rachel
Metadata
Show full item recordUsage
This item's downloads: 18 (view details)
Abstract
Parkinson’s disease is a multifaceted neurodegenerative disorder that currently has no cure. Chronic neuroinflammation is thought to play a crucial role in the progression of the disease, with neuroinflammation and neurotoxicity driving each other in a self-sustaining cycle that is detrimental to the survival of the neurons. Subsequently, the concept of anti-inflammatory disease therapy for the treatment of Parkinson’s disease has emerged in recent years. The cannabinoid CB2 receptor is an attractive target for anti-neuroinflammatory therapy due to its location on microglia and its immunomodulatory effect on these cells. Thus, the overarching aim of this body of research was to investigate the potential of targeting the CB2 receptor for Parkinson’s disease therapy.
Firstly, we assessed the temporal expression of the CB2 receptor in a genetic model of Parkinson’s disease that was induced by administering an adeno-associated viral (AAV) vector which expressed human α-synuclein with the A53T mutation to the rat brain. Following on from this, we endeavoured to enhance the AAV-α-synuclein model using a small molecule α-synuclein aggregator to aid in further studies of the condition. Finally, we investigated the potential of targeting the CB2 receptor for anti-inflammatory disease modification by determining if the pharmacological targeting of this receptor could provide functional neuroprotection in inflammatory rat models.
In the AAV-α-synuclein genetic model of Parkinson’s disease, we did not detect any alterations in CB2 gene expression despite a profound upregulation in human α-synuclein expression in the substantia nigra and the striatum. However, there was a decrease in the striatal levels of the endocannabinoid 2-arachidonylglycerol (2-AG) and of the related N-acylethanolamine N-oleoyl ethanolamide (OEA), indicating a dysregulation of the cannabinoid system in this model. Interestingly, an overall decrease in the expression of microglial and astrocytic markers was observed in the substantia nigra, but these alterations were not accompanied by dopaminergic degeneration.
Further to this, we sought to enhance the AAV-α-synuclein model of Parkinson’s disease by combining AAV-mediated α-synuclein overexpression with FN075-mediated α-synuclein aggregation. The α-synuclein aggregating molecule FN075 combined with the AAV-α-synuclein vectors exhibited a significant increase in the pathogenic phosphorylated form of α-synuclein, with visible anomalous accumulations. However, there was no significant degeneration of the nigrostriatal dopamine neurons in any group.
Finally, we investigated if CB2 agonism produced anti-inflammatory or neuroprotective effects in a viral priming model and in an inflammatory LPS model. We did not observe a significant anti-inflammatory response, but such a role cannot be dismissed, as previous studies have shown the type of model and the particular agonist used results in disparate outcomes.
To conclude, dysregulation of the endocannabinoid system may precede nigrostriatal degeneration, with alterations in the levels of 2-AG and OEA observed in a prodromal AAV-α-synuclein model. However, further studies are required to determine the viability of targeting the CB2 receptor for anti-inflammatory disease modification in Parkinson’s disease. Furthermore, this body of research suggests that, with refinement, the combination of AAV-α-synuclein and FN075 may be a promising novel animal model in which to study Parkinson’s disease in the future.